PYC cites data: what it means for Regulus Therapeutics stock

Published on 10/02/2026 at 03:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PYC cited Regulus phase one B data on September 3, 2026. The USD 1.2 billion market cap values Regulus Therapeutics stock.

RGLS, US75915K3095, Illustration mit AI erstellt.

PYC Therapeutics cited Regulus phase one B data on September 3, 2026, highlighting short-term safety and some efficacy for the kidney-disease program. The USD 1.2 billion market capitalization gives Regulus Therapeutics stock a market-based context while investors assess the clinical evidence.

Phase one B data shape the story

As Investing.com reported on September 3, 2026, PYC Therapeutics described Regulus as having completed a phase one B trial with short-term safety and some efficacy. The cited program targets autosomal dominant polycystic kidney disease, a setting where clinical proof of concept can materially influence the value assigned to a development-stage biotech.

The evidence is still clinical rather than commercial. Regulus has two lead candidates in development, according to Robinhood, which identifies RG-012 and RGLS4326 as the company's lead programs. The company profile also describes Regulus as focused on medicines that target microRNAs.

Two candidates, one clinical focus

BiopharmaWatch lists RGLS4326 and RGLS8429 under Regulus Therapeutics, confirming a two-program clinical pipeline in its October 1, 2026 update. That count matters because development-stage valuation depends on both the lead asset's data and the ability of additional candidates to diversify clinical risk.

The company profile lists 26 employees and a 2007 founding year, while the market capitalization stood at USD 1.2 billion on September 30, 2026, according to Robinhood. Those figures describe a small clinical organization carrying a valuation that depends primarily on future development milestones rather than established product revenue.

What the data means for valuation

The central investor question is whether the reported safety and efficacy signals can support later-stage development. The cited phase one B result supplies a clinical reference point, while the two-candidate pipeline provides a second source of potential value. Regulus remains a biotechnology development story, so trial progress and evidence quality are more relevant than operating revenue at this stage.